News Release

October 27, 2026

PeptiDream Inc.
https://www.peptidream.com/en/
(TSE Prime Market: 4587)
PDRadiopharma Inc.
https://www.pdradiopharma.com/en/

Formal Approval of Location and Signing of Agreement for New Manufacturing Facility at Kazusa Akademia Park, Chiba

KAWASAKI, JAPAN – October 27, 2026 – PeptiDream Inc., a public biopharmaceutical company based in Kawasaki, Japan, focused on the discovery and development of peptide-based therapeutics (CEO: Patrick C. Reid, hereinafter "PeptiDream") and PDRadiopharma Inc. (President: Masato Murakami, Headquarters: Chuo-ku, Tokyo, Japan, hereinafter "PDRadiopharma"), a wholly owned subsidiary of PeptiDream, today announced that its subsidiary, PDRadiopharma, has received formal approval from the Kazusa Akademia Park Research Institute and Related Facilities Promotion Council to move forward with the development of a new manufacturing facility at Kazusa Akademia Park.

PDRadiopharma has entered into an agreement with Chiba Prefecture and the Kazusa Akademia Park Research Institute and Related Facilities Promotion Council regarding the construction of a new radiopharmaceutical manufacturing facility within Kazusa Akademia Park. The approval application was originally submitted by PeptiDream and PDRadiopharma to the Chiba Prefecture Government in December 2024.

PeptiDream and PDRadiopharma are jointly focused on the discovery of innovative radiopharmaceuticals leveraging PeptiDream's proprietary PDPS® (Peptide Discovery Platform System) technology to discover and develop innovative radiopharmaceuticals. In anticipation of the launch of therapeutics and theranostics (*1) utilizing next-generation radionuclides (*2), PeptiDream and PDRadiopharma plan to expand their manufacturing capabilities beyond the existing PDRadiopharma Chiba Plant. The new facility will meet international standards and support domestic supply, as well as future exports to the Asia-Pacific region.

Receipt of this approval represents a key milestone for the project and enables PDRadiopharma to proceed toward a planned construction start in 2027. The new facility is scheduled for completion in 2028. PeptiDream plans to finance the investment through long-term bank loans and is also exploring available government incentive programs, certain tax benefits as well as subsidy programs to help offset the investment costs.

【Overview of New Manufacturing Site】

Location	Production Area 2B, Kazusa Akademia Park, Chiba, Japan
Land Size	57,000 m^2 (approximately 14 acres)
Business	Process development, manufacturing, and shipment of PET products and radiopharmaceuticals (radionuclides: ^{64}Cu, ^{177}Lu, ^{225}Ac, etc.)

Facility Scale	Total floor area: 5,364.46 m² (production building, office and warehouse building, and other facilities)
Investment Amount	Approximately JPY 16.5 billion (breakdown: JPY 11.0 billion for buildings and JPY 5.5 billion for equipment and other costs)
Planned Number of Employees	25
Planned Completion	Anticipated Completion: September 2028

"The formal approval of the location and the signing of this agreement represent an important milestone in the construction of our new manufacturing facility," **said Patrick C. Reid, CEO of PeptiDream**. "*As we continue to expand our pipeline of next-generation targeted radiopharmaceuticals, this facility will provide essential manufacturing capabilities to support their future commercialization and supply to patients in Japan and around the world."*

"Kazusa Akademia Park is an ideal location for our new facility, providing strong connectivity with PeptiDream, our PET laboratories in Kawasaki Chiba Plant and both Haneda and Narita airports," **said Masato Murakami, Executive Vice President of PeptiDream and President of PDRadiopharma.** *" We are deeply grateful for the support of Chiba Prefecture and the relevant organizations in reaching this important milestone. We view this new facility as a key foundation for the future commercialization and global expansion of our radiopharmaceuticals. From this new site, we will build the capabilities to rapidly and reliably deliver our innovative radiopharmaceuticals to as many patients as possible".*

*1 Theranostics: A medical approach that integrates both treatment and diagnosis by using different nuclides for diagnosis and treatment based on the same targeting molecule, such as peptides. Theranostics is expected to have benefits such as effectively selecting patients who are most likely to benefit from treatment and being able to monitor the effectiveness of treatment at any time.

*2 Next-generation radionuclides: PeptiDream and PDRadiopharma are promoting the development of new radiopharmaceuticals using next-generation radionuclides such as ^{225}Ac (an alpha-emitting nuclide that is expected to have a higher killing effect on cancer cells than beta-emitting nuclide) and ^{64}Cu (a nuclide used in PET diagnostic drugs with a longer half-life of approximately 13 hours).

About PeptiDream Inc.
PeptiDream Inc. (Tokyo Stock Exchange Prime Section 4587) is leading the translation of macrocyclic peptides into a whole new class of innovative medicines to address unmet medical needs and improve the quality of life of patients worldwide. In its radiopharmaceutical business, through its wholly-owned subsidiary PDRadiopharma, PeptiDream markets and sells a number of approved radiopharmaceuticals and radiodiagnostics in Japan, as well as leveraging its proprietary Peptide Discovery Platform System (PDPS) technology to discover and develop a deep pipeline of innovative targeted radiotherapeutics and radiodiagnostics, spanning both wholly-owned internal programs and globally partnered programs. In its non-radiopharmaceutical business, PeptiDream is similarly leveraging PDPS to discover and develop a broad and diverse pipeline of investigational peptide therapeutics, peptide drug conjugates (PDC) and multi-functional peptide conjugates (MPC) across an extensive global network of discovery and development partners. PeptiDream is headquartered in Kawasaki, Japan. For more information about our company, science and pipeline, please visit www.peptidream.com/en/.

About PDRadiopharma Inc.

PDRadiopharma Inc. (which joined the PeptiDream Group in 2022) has been a pioneer in radiopharmaceuticals since commencing operations in 1968, providing high-quality radiopharmaceutical products through research and development, manufacturing, and sales. It currently markets 21 radiodiagnostic products (SPECT and PET diagnostics) and eight radiotherapeutic products across three product categories in Japan. In addition, PDRadiopharma and PeptiDream are developing a broad pipeline of radiodiagnostics and radiotherapeutics for the Japanese and global markets. For more information, please visit https://www.pdradiopharma.com/en/.

Inquiries:

PeptiDream Inc.
Contact: Yuko Okimoto, IR & Corporate Communications
Email: info@peptidream.com
Website: https://www.peptidream.com/en/
X: https://x.com/PeptidreamInc
LinkedIn: https://www.linkedin.com/company/peptidream

PDRadiopharma Inc.
Contact: Noriko Tanaka, General Affairs
Email: s-info-hq@pdradiopharma.com
Website: https://www.pdradiopharma.com/en/
X: https://x.com/PDRadiopharma
LinkedIn: https://www.linkedin.com/company/pdradiopharma-inc